Loading
ESG401 is an experimental drug that delivers chemotherapy to cells bearing TROP2. Early breast-cancer response results are being followed by larger trials.
ASCO 2025 abstract 1044 reports 156 patients enrolled in ESG401-101 at the October 23, 2024 cutoff. Distinct efficacy populations included 37 late-line TNBC patients (ORR 35.1%, 95% CI 20.2 to 52.5) and 35 first-line TNBC patients (ORR 83.0%, 95% CI 66.4 to 93.4). These nonrandomized cohorts have different lines of treatment and cannot be pooled or compared directly with phase 3 ADC trials. Grade 3 or higher treatment-related events were mainly neutropenia and leukopenia. The phase 1/2 NCT04892342 is completed; later registered phase 3 development is separate from this early evidence.
Humanized anti-TROP2 IgG1 conjugated to SN-38 through a stable cleavable linker. Connects to TROP2.
1.ESG401's antibody arm binds TROP2 on the surface of the cancer cell.
Country and place are remembered in this browser only. A postcode is sent to OpenStreetMap's Nominatim service to find coordinates when you press the button; nothing else leaves your device.
Query for this drug: (TITLE:"ESG401" OR ABSTRACT:"ESG401") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about ESG401, not a curated reading list.
Shares TROP2, Triple-negative breast cancer (TNBC), HR-positive / HER2-negative breast cancer and the tag pipeline.
Shares TROP2, Triple-negative breast cancer (TNBC) and the tag pipeline.
Shares Qilu Pharmaceutical and the tag pipeline.
Shares Qilu Pharmaceutical and the tag pipeline.
Shares TROP2, Triple-negative breast cancer (TNBC) and the tag pipeline.
Shares TROP2, Triple-negative breast cancer (TNBC), HR-positive / HER2-negative breast cancer and the tag pipeline.
Shares Triple-negative breast cancer (TNBC), HR-positive / HER2-negative breast cancer and the tag pipeline.
Shares Qilu Pharmaceutical and the tag pipeline.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/